Pharma Solutions at IFF’s Post

In this feature with Drug Development & Delivery, Andy Lewis, Chief Scientific Officer, speaks on our #TranslationalPharmaceutics® platform and its benefits to accelerating and controlling the full #drugdevelopment value chain, including implementing adaptive clinical trial designs and transforming the traditional model. Read the full article here: https://bit.ly/4bqABaj

Ultimately, the goal of biotech leaders is to create an innovative product that brings medical value for patients. This cannot be achieved in a single step, and we help biotechs along the journey to reach that goal, structuring the drug development process into a series of clear and reachable value inflection points. Learn more about how we support our biotech clients or connect with our delegates onsite at #SwissBiotechDay: https://lnkd.in/dVAEZRKN #biotech #drugdevelopment

For more than ten years, sponsors and researchers have discussed "patient-centric drug development," but clinical trials have seen little transformation. To genuinely elevate patient experiences and advance health outcomes, it's essential to go beyond minor innovations and adopt a comprehensive paradigm shift. https://gag.gl/wE0cVC #DrugDevelopment #FortreaConsulting John Doyle, Dr.P.H.

Patient registries are an important means of assessing drug safety and effectiveness. This article by IQVIA’s Emily Bratton and Ian Bonzani explores how technology innovations can increase registry data and generate high quality RWE to meet stakeholder needs. https://bit.ly/49Jjgu5

Why Patient Registries are Game-Changers for the Middle East 🌍 📊 In countries like Qatar, Kuwait, Bahrain and Oman, leveraging technology to build advanced patient registries isn’t just innovation—it’s a necessity! 💡📊 These registries collect real-world evidence, enabling personalised care and smarter healthcare decisions. 🚑🎯 By embracing cutting-edge tech, the Middle East can unlock superior data insights, tackle unique regional health challenges 💪, and drive research excellence. 🚀 The result? Improved patient outcomes and optimised resources for the future. 🏥✨ Let’s lead the healthcare revolution—one registry at a time! 🌟 #HealthcareInnovation #MiddleEast #DataDrivenHealthcare #PatientCentricity #IQVIA #ResearchExcellence #HealthTech #RealWorldEvidence Rauf Mohammed Dr Bakul Mukherjee, MD, MSc (Reg. Affairs Health Policy)

I completely agree with the points raised in this article. Patient registries are indeed crucial for monitoring drug safety and effectiveness. The integration of technology to enhance these registries is a game-changer. By leveraging #innovations, we can gather more comprehensive #data and produce high-quality real-world evidence (RWE). This not only benefits stakeholders but also ensures better patient outcomes. It's exciting to see how advancements in technology can drive improvements in #healthcare research and practice. We are talking about #AI a lot and we hope that this tehnology will change the healthcare, it will, but first, we need to get right data, clean data to algorithms to learn!

Did you miss our webinar yesterday 😱? No worries! You can still watch the recording of the "Find your star. Delivering business value with Quantum-Aided Drug Design" webinar here: https://lnkd.in/gQEGAUVd

For more than ten years, sponsors and researchers have discussed "patient-centric drug development," but clinical trials have mostly stayed the same. To genuinely improve patient experiences and health outcomes, it's essential to go beyond minor innovations and adopt a comprehensive paradigm shift. https://gag.gl/wE0cVC #DrugDevelopment #FortreaConsulting John Doyle, Dr.P.H.

Improving The Clinical Trial Ecosystem: A Call To Stakeholder Alignment https://lnkd.in/edrwxW_U - By Rob Freishtat, MD, MPH In theory, all of the stakeholders in drug development — investors, scientists, regulators, and patients — share the common goal of creating safe and effective drugs.

For more than ten years, sponsors and researchers have discussed "patient-centric drug development," but clinical trials have mostly stayed the same. To genuinely improve patient experiences and health outcomes, it's essential to advance beyond minor innovations and adopt a comprehensive paradigm shift. https://gag.gl/wE0cVC #DrugDevelopment #FortreaConsulting John Doyle, Dr.P.H.